Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program-Reference-Cited by-同舟云学术

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

Published:2019-03-13 Issue:5 Volume:94 Page:546-553
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Bussel James B.¹,Arnold Donald M.²³,Boxer Michael A.⁴,Cooper Nichola⁵,Mayer Jiri⁶,Zayed Hany⁷,Tong Sandra⁷,Duliege Anne‐Marie⁷

Affiliation:

1. Division of Pediatric Hematology/Oncology, Department of PediatricsWeill Cornell Medicine New York New York

2. Department of MedicineMichael G. DeGroote School of Medicine, McMaster University, and McMaster Centre for Transfusion Research, Hamilton Health Sciences Hamilton Ontario Canada

3. Canadian Blood Services Hamilton Ontario Canada

4. Arizona Oncology Associates Tucson Arizona

5. Imperial College Healthcare NHS Trust, Hammersmith Hospital London United Kingdom

6. Fakultni nemocnice Brno Brno Czech Republic

7. Rigel Pharmaceuticals Inc. South San Francisco California

Funder

Rigel Pharmaceuticals, Inc

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25444

Reference34 articles.

1. The Incidence of Idiopathic Thrombocytopenic Purpura in Adults Increases With Age

2. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports

3. Prevalence of immune thrombocytopenia: analyses of administrative data

4. Immune thrombocytopenic purpura: epidemiology and implications for patients

5. The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activation of the HMGB1‐TLR4 pathway impacts the functionality of bone marrow mesenchymal stem cells and disrupts macrophage polarization in immune thrombocytopenia;British Journal of Haematology;2024-08-21

2. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice;Blood;2024-08-08

3. Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies;Expert Review of Hematology;2024-08-06

4. 2025 update on clinical trials in immune thrombocytopenia;American Journal of Hematology;2024-08-06

5. Sovleplenib in immune thrombocytopenia;The Lancet Haematology;2024-08